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Background: To be successful, cost control efforts must target Medicaid Managed Care (MMC) beneficiaries likely
to incur high costs. The critical question is how to identify potential high cost beneficiaries with simple,
reproducible, transparent, auditable criteria. Our objective in this analysis was to evaluate whether the total burden
of comorbidity, assessed by the Charlson comorbidity index, could identify MMC beneficiaries who incurred high
health care costs.
Methods: The MetroPlus MMC claims database was use to analyze six months of claims data from 07/07-12/07; the
analysis focused on the total amount paid. Age, gender, Charlson comorbidity score, serious mental illness and
pregnancy were analyzed as predictors of total costs.
Results: We evaluated the cost profile of 4,614 beneficiaries enrolled at MetroPlus, an MMC plan. As hypothesized,
the comorbidity index was a key correlate of total costs (p < .01). Yearly costs were more related to the total burden
of comorbidity than any specific comorbid disease. For adults, in addition to comorbidity (p < .01) both serious
mental illness (p < .01) and pregnancy (p < .01) were also related to total costs, while age, drug addiction and
gender were not. The model with age, gender, comorbidity, serious mental illness, pregnancy and addiction
explained 20% of the variance in total costs. In children, comorbidity (p < .01), serious mental illness (p < .01),
addiction (p < .03) and pregnancy (p < .01) were associated with log cost; the model with those variables explained
6% of the variance in costs.
Conclusions: Comorbidity can be used to identify MMC beneficiaries most likely to have high costs.
Keywords: Comorbidity, Multiple chronic conditions, Medicaid, Prediction of cost, Predictive models, Cost
containment, Managed care, Cost analysis, Prediction rulesBackground
States have steadily increased mandates for Medicaid re-
cipients to enroll in Medicaid Managed Care (MMC).
As a result, 70% of the 60 million Medicaid beneficiaries
are now in a MMC plan [1]. While some specific MMC
programs have shown potential cost savings primarily by
reducing inpatient use [2], an analysis of the 1991-2003
experience with MMC mandates in 50 states found that
their impact on overall costs was negligible [3].* Correspondence: mecharl@med.cornell.edu
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unless otherwise stated.It has been estimated that under the Patient Protection
and Affordable Care Act 25%, of U.S. residents are likely
to be insured by Medicaid [4], increasing the need to
identify potential high cost MMC beneficiaries with sim-
ple, reproducible, and auditable criteria that can be ap-
plied prospectively as patients enroll.
Previously among primary care patients, we found
that average yearly total costs rose exponentially as
the Charlson comorbidity rose above 4 [5]. However,
the weakness of this prior study was that our cost
data captured only costs of primary care patients at one
health center (i.e., New York Presbyterian), and not out-
patient or inpatient costs for external providers [5]. The
Charlson comorbidity index can be assessed by question-
naire, analysis of medical records or claims data [6,7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plan, our objective was to evaluate whether the comorbid-
ity index identified Medicaid beneficiaries who incurred
high health care costs, controlling for other important
contributors to costs in Medicaid patients, such as mental
illness and pregnancy [8]. Based on our previous work, we
hypothesized that as the comorbidity index rose above 4,
there would be an exponential rise in mean yearly cost. If
so, the comorbidity index, which can be assessed during a
short interview, could be used to identify patients likely to
incur high costs at the time of enrollment including those
who will be newly enrolled under the Affordable Care Act.
The population
Lincoln Medical and Mental Health Center (Lincoln),
serves the 654,360 predominately Latino (69%) and African
American (29%) residents of the South Bronx, who have a
median household income of $16,000. Lincoln Medical
and Mental Health Center, is part of New York City’s
Health and Hospitals Corporation (HHC) - a part owner
of Metro Plus which is an MMC plan that assumes risk
on all patients assigned to its primary care physicians. The
study population includes all enrollees in the MMC plan
who have primary care in the Lincoln system, including
those enrolled through Medicaid, Child Health Plus,
Family Health Plus, and Medicaid HIV. It does not in-
clude Medicare/Medicaid patients.
The project was reviewed and approved by the IRB
at Lincoln Medical and Mental Health Center, at Weill
Cornell Medical College and the HHC central research
office. All data was de-identified. For research purposes,
the data provided by Metroplus was restricted only to
patients who had an assigned primary care physician at
Lincoln.
Sample
The MetroPlus claims database was used to identify
those patients for whom Lincoln was assigned as the pri-
mary care provider. The analysis focused on patients
who had an assigned primary care provider at Lincoln
between 07/07-12/07. There were 4,614 MetroPlus
members who met the criteria: 2,218 adults and 2,396
children.
Study variables
The age, gender, primary language, line of service (Medicaid,
Child Health Plus, Family Health Plus, Medicaid HIV),
and zip code of residence were documented. Chronic
diseases were ascertained from the ICD-9 codes as-
signed by MetroPlus MMC when patients received any
service.
The Charlson comorbidity score was used to assess
the aggregate burden of chronic disease [9]. The index
assigns weights for specific diseases and the total scoreis calculated by adding the weights [6]. The 23 chronic
diseases (including one medication) that comprise the
Charlson Comorbidity Index and their assigned weights
are as follows:
Weight of one: cerebrovascular disease, congestive
heart failure, connective tissue disease, chronic
obstructive pulmonary disease, dementia, depression,
diabetes, hypertension, mild liver disease, myocardial
infarction, peripheral vascular, ulcer disease or the use
of warfarin;
Weight of two: hemiplegia, moderate/severe renal
disease, diabetes with end organ damage, any tumor,
leukemia, lymphoma or skin ulcers/cellulitis;
Weight of three: moderate to severe liver disease;
Weight of 6: metastatic solid tumor or AIDS.
Aggregate ICD-9 codes were used to ascertain the
Charlson index using the Deyo coding strategy [7]. In
addition to chronic conditions that are included in the
comorbidity index, substance abuse, mental illness and
pregnancy were also recorded. Patients with ICD-9 codes
of 303 or 305 were coded as addiction (drug or alcohol)
and those with ICD-9 codes of 290, 300 or 307-317 as ser-
ious mental illness. Patients with ICD-9 codes of 640-677
were classified as pregnant.
Costs
Six months of claims data from 07/07-12/07 from Metro-
Plus MMC costs were evaluated. Costs were assessed by
setting and type. The MMC covered inpatient, outpatient,
ER, laboratory tests, and prescription drugs; it did not
cover dental services. Total costs were defined as the total
claims paid; claims that were not paid did not contribute
to total costs.
Statistical analysis
Adjusted costs for patients with specific chronic diseases
were analyzed in order to document the cost of that dis-
ease alone, controlling for comorbidity. The adjusted co-
morbidity index was found by subtracting the weight for
each disease from the comorbidity index; an index of
zero means the patient had just one chronic disease. For
example, when evaluating costs associated with diabetes,
a patient with only diabetes ( and a comorbidity score of
1) would have an adjusted comorbidity score of 0; how-
ever, a patient with diabetes and hypertension would
have an adjusted comorbidity score of 1.
A two part regression modelling framework was used for
modeling log total health care cost. Log total costs are
used in the regression modeling in order to correct skew-
ness. The first part of the two-part model is a binary
outcome model that describes the distinction between
non-users (zero cost) and users of services (non-zero
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describes the distribution of log total health care cost for
patients who used services. Separate (two part) regression
models were developed for adults and children (age < 18).
These regressions were all controlled for age and gender.
Addiction (drug or alcohol) and pregnancy were also
assessed in both the adult and child models [10].
Quantile regression was employed to assess the rela-
tionship between predictors and the upper 5% and 10%
of the cost distribution, controlling for age, gender and
mental health diagnoses [11]. Quantile regression fo-
cuses on the upper tail of the cost distribution so that
patients with zero costs in the lower tail of the distribu-
tion do not heavily affect the estimates. The pseudo R2
is the measure of model fit.
Results
Overall, as shown in Table 1, 48.1% of the MMC bene-
ficiaries were adults, 72% women, with an average age
of 45.7 ± 12.6 years (a range of 18 to 73 years), while
51.9% were children with an average age of 7.6 ± 4.9 years
(a range of .01 to 17.9 years). Of the adults, 1.8% were over
65 years of age. Of the children, 4.4% were less than one
year of age. Overall, 86.9% of all children were enrolled
through standard Medicaid, 2.2% through Child Health
Plus, a NY State insurance for children under the age
of 19 who are not eligible for Medicaid; 8.9% through
Family Health Plus, a NY State plan for families not eli-
gible for Medicaid; 0.7% through a commercial MetroPlusTable 1 Demographic and clinical characteristics of
beneficiaries
Adults (n = 2,218) Children (n = 2,396)
Age ( sd) 45.7 ± 12.6 7.6 ± 4.9
Female 71.1% 49.2%
Medicaid 78.2% 95.0%
Child health plus 0% 4.3%
Family health plus 18.5% 0%
Pregnancy 4.2% 0.2%
Addiction 4.2% 0.3%




Asthma or COPD 15.2% 11.4%
Depression 7.1% 0.3%
Liver disease£ 3.7% 0.1%
HIV/AIDS 2.6% 0.4%
∞0.2% had metastatic disease.
€2.3% had end organ damage.
£2.9% with moderate-severe disease.plan; and 1.3%, through a Medicaid HIV special needs
plan. There were only 8 patients who were enrolled in
Medicaid at the time of hospitalization. English was the
primary language for 62% and Spanish for 36% of the
patients.
Table 2 shows the distribution of beneficiaries and
costs according to the comorbidity index. Overall, the
8.3% of adults with a comorbidity index ≥4 incurred
30.1% of the costs. Among the children, a vast majority
had a comorbidity score of 0. Among children, the 12.7%
with one or more chronic illnesses incurred 41.6% of the
costs. The most common chronic diseases in children
were asthma (11.3%) and diabetes (0.4%). The children
with asthma had mean costs of $1,291 ± $7,683, while
those with diabetes had mean costs of $2,031 ± $2,013,
respectively. Costs did not differ according to enrollment
plan, except for Medicaid HIV, where the costs were sig-
nificantly higher (p < .04).
Overall, as comorbidity increased, total costs increased
(p < .01). Costs for each chronic condition did not differ
at lower levels of comorbidity. Costs according to spe-
cific chronic illnesses were also evaluated. Figure 1 shows
the costs for chronic diseases impacting at least 100 bene-
ficiaries according to the adjusted level of comorbidity. It
demonstrates that costs are more a function of the total
burden of comorbidity than of any specific comorbid dis-
ease. Figure 2 shows the distribution of patients according
to the adjusted comorbidity index; the vast majority of
beneficiaries, regardless of specific chronic illness, had a
comorbidity index of zero or one.
The comorbidity index and total visits were correlated
for adults (R = .29) and children (R = .21); however; the
comorbidity index did not increase until the number of
visits exceeded 20.
Pregnancy
The 94 women who were pregnant, including 4 adoles-
cents, had a significantly increased cost of $4,104 ± $3,865
(p < .01). Of the pregnant women, 75 with a comorbidity
score of 0 had an average cost of $3,621, while the 16
women with a comorbidity score of 1 had costs of $5,470.
Only 3 pregnant women had scores of 3 or more; they
had average costs of $8,902.
Mental illness
Costs for the 190 patients with severe mental illness, in-
cluding major depression, bipolar illness, and schizo-
phrenia, were also significantly higher (p < .003). Of these
patients with serious mental illnesses, 86% were adults,
and 14% children; both groups had similar costs. Of the
100 patients who had an addiction, 93% were adults, and
7% children. Overall 3% of those with a comorbidity score
of 0-1 had mental illness, vs. 15% of those with a score ≥2
(p < .01). Controlling for age, gender, comorbidity and














0¥ 1,203 54.2% $886,611 30.9% $737 $774
1 605 27.3% $459,195 16.0% $760 $741
2-3 137 6.2% $299,208 10.4% $2,184 $2,100
≥4 183 8.3% $843,996 29.4% $4,672 $4,553
All 2,128 $2,489,010
Children
0 2,089 87.2% $607,899 62.1% $291 $295
1 286 11.9% $336,622 34.4% $1,177 $1,152
2-3 5 0.2% $6,250 0.6% $1,251 $1,442
≥4 12 0.5% $12,228 1.3% $1,020 $111
All 2,392 $962,999
¥ excludes 94 pregnant women 75 pregnant women with a comorbidity score of 1 had an average cost of $3,621, while the 16 women with a comorbidity score
of 1 had costs of $5,470.
Adjusted costs are adjusted for age, gender, mental health, and addiction.
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the costs than those without ($1,345 vs. $801).
Hospitalization as a driver of costs
As shown in Table 3, the rate of hospitalization and
repeated hospitalization increased with increasing co-
morbidity (p < .01 for both). Two-thirds of the patients
hospitalized were adults, while one-third were children
(p < .01). Patients who were hospitalized incurred mean
costs of $8,996, while those not hospitalized had mean
costs of $263 (p < .0001). Table 4 shows the average costs
for patients according to comorbidity and total hospitali-
zations. Once comorbidity was taken into account, the
hospitalization costs did not differ between children and
adults (p < .7).Figure 1 Costs according to specific chronic diseases and adjusted co
subtracting the weight for each disease from the comorbidity index; an indRegression models
Results for the regression analysis for the two part model
of log total costs are given in Table 5. For a pooled mo-
del of adults and children of log total costs, the comor-
bidity index was a key correlate of total costs (p < .01,
95% CI [.11, .14]). Adults: In addition to comorbidity
(p < .01, 95% CI [.10, .14]), serious mental illness (p < .01,
95% CI [.06, .27]), and pregnancy (p < .01, 95% CI [.81,
1.07]) were also correlated with costs, while age, drug
addiction and gender were not. The model with age, gen-
der, comorbidity, mental illness, pregnancy, and drug/alco-
hol addiction explained 20% of the variance in total costs
(R2 = .20) Children: In children, comorbidity ( p < .01, 95%
CI [.10, .19]), serious mental illness (p < .01, 95% CI [.11,
.53]), drug/alcohol addiction ( p < .03, 95% CI [.03, .81]),morbidity score. The adjusted comorbidity index was found by
ex of zero means the patient had just the one chronic disease.
Figure 2 The distribution of patients with specific chronic diseases according to their adjusted comorbidity score.
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with log cost, however, age and gender were not signifi-
cantly related to log total costs; the explained variance was
6% (R2 = .06).
Quantile regression was used to evaluate predictors of
the top 5% and 10% of cost; the results are presented in
Table 6. The comorbidity index was significantly cor-
related with the top 5% and top 10% of costs for the
pooled sample, as well as for adults and children sepa-
rately. For the top 10%, pregnancy and serious mental
illness were significantly associated with log total costs
in the adult sample while age was negatively correlated
with log total costs in the child sample.
Discussion
This study showed that costs for MMC beneficiaries
were primarily driven by the aggregate burden of co-
morbid disease, not by individual chronic illnesses. This
echoes the findings of other studies about multiple chro-
nic diseases as drivers of cost [12-14]. Although comor-








0-1 3.7% 1.0% 4.7%
2-3 13.3% 3.5% 16.8%
≥4 10.2% 6.6% 16.8%‘other diseases’ that can confound the outcomes of pa-
tients with a specific chronic illness, comorbidity is in-
trinsically a measure of the aggregate burden of disease.
For MMC programs, a critical question is how to con-
trol costs. To reduce costs, efforts have to focus on
MMC beneficiaries most likely to incur high costs [15].
Some MMC efforts to decrease costs have targeted indi-
viduals who were high cost or high utilizers in the prior
year [16-18] and others have focused on patients with
specific chronic diseases [19-22]. However, most of these
programs have not reduced costs [1,22-24].
MMC cost reduction efforts have also focused on
beneficiaries who are predicted to have high costs using
claims based models [22-28]. Most efforts to reduce costs
have not taken comorbidity into account [20,22,28]. How-
ever, in this analysis, the 8% of patients with a comorbidity
burden of four or more had 30% of costs. This data shows
that strategies focused on a single chronic disease per se
cannot efficiently target patients with a high burden of co-
morbidity who have high costs.Table 4 Average cost according to number of








0-1 $ 214 $ 5,511 $13,860
2-3 $ 926 $ 4,651 $24,713
≥4 $1,441 $14,468 $27,057
Table 5 Regression analysis for the two part model of log




p Adults p Child p
Comorbidity 0.13 <.01 0.13 <.01 0.15 <.01
(16.66) (14.89) (6.68)
Age 0.00286 <.01 0.00059 -0.00466
(5.62) (0.52) (1.76)
Female 0.00 0.04 -0.05
(0.00) (1.22) (1.91)
Mental illness 0.19 0.16 0.32
(4.19) <.01 (3.09) <.01 (2.98) <.01
Addiction 0.15 0.13 0.42
(2.46) <.05 (1.91) (2.13) <.05
Pregnancy 1.02 0.95 1.48
(17.28) <.01 (14.49) <.01 (4.93) <.01
Intercept 2.23 2.33 2.29
(120.44) <.01 (40.47) <.01 (83.58) <.01
R2 0.21 0.20 0.06
N 3,427 1,881 1,546
Observed log10 Total Cost regression coefficients from a two part regression
model (equations (1) and (2) in the Appendix). The coefficients for the zero
inflation part of the two part model are not displayed. T-statistics are
in parentheses.
Table 6 Quantile regression analysis of correlates of the top 1
t statistics
Top 10% combined Top 5% combined















Pseudo R2 0.15 0.12
N 3,427 3,427
Observed log10 Total Cost regression coefficients from quantile regressions. The co
T-statistics are in parentheses.
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itional methodologic challenges [18]. Patients with such
gaps in enrollment (churning in and out of Medicaid)
have been shown to have highly variable costs [25].
Limitations
The major limitation is that our analysis focused on
claims and cost data for 6 months only. We could not
ascertain whether costs differed by season, since we had
only 6 months of data. It would have been preferable to
have a full year of data. We did not evaluate patients
who were cycling in and out of enrollment, who are
known to have greater cost variability [25]. In addition,
our analysis focused on non-disabled beneficiaries [29].
Another limitation is that the comorbidity index has not
been validated for children or pregnant women. While
costs are clearly higher among pregnant woman when
compared to those with equivalent comorbidity burdens,
the results for pregnant women have to be interpreted
with caution because the subgroup is small.
Another limitation is that this study involves one MMC
plan, based at one hospital in NYC. A recent comprehen-
sive synthesis has pointed out that Medicaid is not a single
program but a diverse group of state run programs, and
that as a result it is hard to generalize about the impact of
MMC on costs [1]. Thus, by this analysis alone, we cannot
be certain that these findings would be applicable to other
states or plans [1]. However, in analyses of two other0% and top 5% of costs: Regression coefficients and
Top 10% of adults Top 10% child
p p p
0.18 0.33










<.01 (6.69) <.01 (0.82)
3.03 3.43
<.01 (26.50) <.01 (31.06) <.01
0.16 0.07
1,881 1,546
efficients for the zero inflation part of the two part model are not displayed.
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morbidity and costs [5,30].
Conclusion
Patients with higher comorbidity incur higher costs, sug-
gesting that high comorbidity patients may be a key tar-
get for cost savings in MMC. The comorbidity score
provides a reproducible, valid method of identifying pa-
tients with multiple chronic diseases, who should be tar-
gets for cost-saving efforts.
Appendix
Statisical methods
In a two-part model, explanatory variables often play dif-
ferent roles in the two parts of the model. Since the non-
zero expenditure data are always positive and heavily
skewed to the right, they are modeled with a lognormal
distribution. Let Zi denote the observed total cost for
the ith subject and Xi represent a vector of subject specific
characteristics. With inflated zero values, the observed
costs are assumed to represent realizations of random var-
iables that have probability distributions describable by a
mixture of a point mass at zero and a continuous distri-
bution. That is, Zi = I [Y1i > 0] × 10
Y2i, where Y1i and Y2i
represent two latent random variables, I [A] denotes the
indicator of the event A (=1 if A occurs and = 0 otherwise).
Intuitively, Y1i regulates when zero costs occurs and Y2i is
the logarithm (base 10) of non-zero costs. Zhang et al.
[30] extend the two-part structure in Duan [31] to model
the distributions of the two latent random variables Y1i
and Y2i. This model is at the individual level and adjusts
for individual level characteristics. Specifically,
Zi ¼ I Y 1i > 0½   10Y2i
Model 1 : Y 1i ¼ α0 þ α1X1i þ ε1i ε1i e N 0; 1ð Þ
ð1Þ




In these models, the covariates X1i and X2i can be dif-
ferent subsets of the complete set of observed charac-
teristics, Xi and the variance of ε1i is set to one for
identifiability. A consequence of Model 2 is that the actual
nonzero costs are specified as a log-normally distributed
random variable. An important feature of a log-normally
distributed random variable model is the distribution is
skewed and that the variance is exponentially increasing
in the levels of the X2i [30]. Estimation for the models de-
fined by (1) and (2) is carried out using maximum likeli-
hood estimation.
In the regression models, we use Model 1 to model
the zero cost and Model 2 to model the cost level. Weuse the comorbidity index age, gender, comorbidity, men-
tal illness, pregnancy, and drug/alcohol addiction as ex-
planatory variables. One often defines the log normal
distribution in terms of the natural logarithm, rather than
base 10 used here, but other logarithmic bases lead to the
same family of distributions with rescaled parameters.
Abbreviation
MMC: Medicaid managed care.
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